Suppr超能文献

影响抗逆转录病毒药物中枢神经系统渗透的药代动力学、药物遗传学及其他因素

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals.

作者信息

Nwogu Jacinta Nwamaka, Ma Qing, Babalola Chinedum Peace, Adedeji Waheed Adeola, Morse Gene D, Taiwo Babafemi

机构信息

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria; Centre for Drug Discovery Development and Production, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria.

School of Pharmacy and Pharmaceutical Sciences and New York State Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, NY 14203, USA; Pharmacy Practice (Medicine and Pediatrics), School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, NY 14214, USA; Center for Integrated Global Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA.

出版信息

AIDS Res Treat. 2016;2016:2587094. doi: 10.1155/2016/2587094. Epub 2016 Sep 29.

Abstract

Neurological complications associated with the human immunodeficiency virus (HIV) are a matter of great concern. While antiretroviral (ARV) drugs are the cornerstone of HIV treatment and typically produce neurological benefit, some ARV drugs have limited CNS penetration while others have been associated with neurotoxicity. CNS penetration is a function of several factors including sieving role of blood-brain and blood-CSF barriers and activity of innate drug transporters. Other factors are related to pharmacokinetics and pharmacogenetics of the specific ARV agent or mediated by drug interactions, local inflammation, and blood flow. In this review, we provide an overview of the various factors influencing CNS penetration of ARV drugs with an emphasis on those commonly used in sub-Saharan Africa. We also summarize some key associations between ARV drug penetration, CNS efficacy, and neurotoxicity.

摘要

与人类免疫缺陷病毒(HIV)相关的神经并发症是一个备受关注的问题。虽然抗逆转录病毒(ARV)药物是HIV治疗的基石,通常能带来神经方面的益处,但一些ARV药物在中枢神经系统(CNS)中的渗透有限,而其他一些药物则与神经毒性有关。CNS渗透是多种因素的作用结果,包括血脑屏障和血脑脊液屏障的筛选作用以及天然药物转运体的活性。其他因素则与特定ARV药物的药代动力学和药物遗传学有关,或由药物相互作用、局部炎症和血流介导。在本综述中,我们概述了影响ARV药物CNS渗透的各种因素,重点关注撒哈拉以南非洲地区常用的药物。我们还总结了ARV药物渗透、CNS疗效和神经毒性之间的一些关键关联。

相似文献

1
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals.
AIDS Res Treat. 2016;2016:2587094. doi: 10.1155/2016/2587094. Epub 2016 Sep 29.
4
Correlates of antiretroviral coverage for prevention of mother-to-child transmission of HIV in sub-Saharan Africa.
AIDS Care. 2019 Oct;31(10):1255-1260. doi: 10.1080/09540121.2019.1587364. Epub 2019 Mar 4.
5
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.
J Antimicrob Chemother. 2014 Jan;69(1):241-5. doi: 10.1093/jac/dkt339. Epub 2013 Aug 23.

引用本文的文献

2
The role of pharmacomicrobiomics in HIV prevention, treatment, and women's health.
Microbiome. 2024 Dec 3;12(1):254. doi: 10.1186/s40168-024-01953-3.
5
Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management.
Nat Rev Neurol. 2023 Nov;19(11):668-687. doi: 10.1038/s41582-023-00879-y. Epub 2023 Oct 10.
8
Nanodelivery of antiretroviral drugs to nervous tissues.
Front Pharmacol. 2022 Nov 8;13:1025160. doi: 10.3389/fphar.2022.1025160. eCollection 2022.
9
A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0027422. doi: 10.1128/aac.00274-22. Epub 2022 Jul 19.
10
Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis.
Neurotherapeutics. 2022 Jul;19(4):1085-1101. doi: 10.1007/s13311-022-01233-8. Epub 2022 Apr 12.

本文引用的文献

3
Dysfunction of brain pericytes in chronic neuroinflammation.
J Cereb Blood Flow Metab. 2016 Apr;36(4):794-807. doi: 10.1177/0271678X15606149. Epub 2015 Sep 30.
4
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
Clin Pharmacol Ther. 2016 Apr;99(4):363-9. doi: 10.1002/cpt.269. Epub 2015 Nov 9.
5
Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
J Neurovirol. 2016 Apr;22(2):170-8. doi: 10.1007/s13365-015-0382-7. Epub 2015 Sep 25.
6
Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz.
Germs. 2015 Sep 1;5(3):83-91. doi: 10.11599/germs.2015.1075. eCollection 2015 Sep.
7
Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition.
Pharmaceuticals (Basel). 2015 Sep 21;8(3):637-63. doi: 10.3390/ph8030637.
9
Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients.
J Neurovirol. 2016 Feb;22(1):88-92. doi: 10.1007/s13365-015-0371-x. Epub 2015 Aug 6.
10
Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia.
Open Forum Infect Dis. 2015 Jul 1;2(3):ofv085. doi: 10.1093/ofid/ofv085. eCollection 2015 Sep.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验